A Phase 2 interventional study of TCD601 and Tacrolimus (TAC) in Kidney Transplantation, sponsored by ITB-Med LLC. Terminated at 7 sites in 3 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by ITB-Med LLC · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of TCD601 when compared to rATG in de novo renal transplant patients.
ITB-Med LLC is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TCD601 0.2 mg/kg administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
Biological: TCD601 · Drug: Tacrolimus (TAC) · Drug: Corticosteroids (CS) · Drug: Mycophenolate Mofetil (MMF)
TCD601 0.6 mg/kg administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
Biological: TCD601 · Drug: Tacrolimus (TAC) · Drug: Corticosteroids (CS) · Drug: Mycophenolate Mofetil (MMF)
TCD601 1.7 mg/kg administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
Biological: TCD601 · Drug: Tacrolimus (TAC) · Drug: Corticosteroids (CS) · Drug: Mycophenolate Mofetil (MMF)
TCD601 5.0 mg/kg administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
Biological: TCD601 · Drug: Tacrolimus (TAC) · Drug: Corticosteroids (CS) · Drug: Mycophenolate Mofetil (MMF)
ATG 1.5 mg/kg administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
Drug: Tacrolimus (TAC) · Drug: Corticosteroids (CS) · Drug: Mycophenolate Mofetil (MMF) · Drug: ATG
Investigational Product
Also known as: Siplizumab
Standard of Care Concomitant Immunosuppression
Standard of Care Concomitant Immunosuppression
Standard of Care Concomitant Immunosuppression
Standard of Care induction therapy in solid organ transplantation
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v5.0.
Time frame: 12 months
Measure Peak TCD601 Plasma Concentration (Cmax) Over Time.
The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration.
Time frame: 12 months
Measure the Area Under the TCD601 Plasma Concentration Versus Time Curve (AUC).
The AUC from time zero to the last measurable concentration sampling time.
Time frame: 12 months
The Incidence of Allograft Rejection at 12 Months Post-Transplant
Time frame: 12 months
To Assess Renal Function Over Time
Time frame: 12 months
| Milestone | Arm 1 | Arm 2 | Arm 3 | Arm 4 | Arm 5 |
|---|---|---|---|---|---|
| Started | 6 | 5 | 8 | 8 | 5 |
| Completed | 5 | 4 | 7 | 0 | 3 |
| Not completed | 1 | 1 | 1 | 8 | 2 |
| Participants | Arm 1 | Arm 2 | Arm 3 | Arm 4 | Arm 5 |
|---|---|---|---|---|---|
| At least 1 TEAE — Yes | 6 | 5 | 8 | 8 | 5 |
| At least 1 TEAE — No | 0 | 0 | 0 | 0 | 0 |
| At least 1 TEAE Related to Study Medicatoin — Yes | 6 | 4 | 8 | 8 | 5 |
| At least 1 TEAE Related to Study Medicatoin — No | 0 | 1 | 0 | 0 | 0 |
| At least 1 SAE — Yes | 3 | 1 | 4 | 4 | 0 |
| At least 1 SAE — No | 3 | 4 | 4 | 4 | 5 |
| At least 1 TEAE leading to Study Discontinuation — Yes | 0 | 0 | 1 | 1 | 0 |
| At least 1 TEAE leading to Study Discontinuation — No | 6 | 5 | 7 | 7 | 5 |
| At least 1 TEAE leading to Dose adjustment — Yes | 0 | 0 | 0 | 0 | 0 |
| At least 1 TEAE leading to Dose adjustment — No | 6 | 5 | 8 | 8 | 5 |
| At least 1 TEAE leading to Dose interruption — Yes | 0 | 0 | 0 | 1 | 0 |
| At least 1 TEAE leading to Dose interruption — No | 6 | 5 | 8 | 7 | 5 |
| At least 1 TEAE leading to Study Medication Discontinuation — Yes | 0 | 0 | 1 | 2 | 0 |
| At least 1 TEAE leading to Study Medication Discontinuation — No | 6 | 5 | 7 | 6 | 5 |
| At least 1 Infection — Yes | 6 | 2 | 8 | 2 | 2 |
| At least 1 Infection — No | 0 | 3 | 0 | 6 | 3 |
| At least 1 Serious Infection — Yes | 0 | 0 | 1 | 0 | 0 |
| At least 1 Serious Infection — No | 6 | 5 | 7 | 8 | 5 |
| At least 1 SAE related to Study Medication — Yes | 0 | 0 | 2 | 3 | 0 |
| At least 1 SAE related to Study Medication — No | 6 | 5 | 6 | 5 | 5 |
The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration.
| ug/mL | Arm 1 | Arm 2 | Arm 3 | Arm 4 |
|---|---|---|---|---|
| Measure Peak TCD601 Plasma Concentration (Cmax) Over Time. | 4.3 ± 0.578 | 12.8 ± 1.96 | 50.6 ± 9.79 | 135 ± 11.8 |
The AUC from time zero to the last measurable concentration sampling time.
| ug/mLxday | Arm 1 | Arm 2 | Arm 3 | Arm 4 |
|---|---|---|---|---|
| Measure the Area Under the TCD601 Plasma Concentration Versus Time Curve (AUC). | 26.2 ± 4.67 | 95.4 ± 29.3 | 627 ± 249 | 1910 ± 389 |
| Participants | Arm 1 | Arm 2 | Arm 3 | Arm 4 | Arm 5 |
|---|---|---|---|---|---|
| The Incidence of Allograft Rejection at 12 Months Post-Transplant | 0 | 0 | 1 | 0 | 0 |
| mL/min/1.73m^2 | Arm 1 | Arm 2 | Arm 3 | Arm 4 | Arm 5 |
|---|---|---|---|---|---|
| Baseline | 32.99 ± 15.671 | 61.8 ± 20.521 | 51.85 ± 12.011 | 59.45 ± 12.676 | 51.17 ± 8.376 |
| Month 3 | 40.51 ± 14.339 | 67.11 ± 21.028 | 52.53 ± 9.416 | 57.92 ± 9.412 | 53.48 ± 4.918 |
| Month 6 | 37.98 ± 8.236 | 64.75 ± 11.501 | 52.64 ± 8.727 | 54.64 ± 21.590 | 58.93 ± 4.918 |
| Month 12 | 45.15 ± 9.295 | 70.06 ± 16.051 | 56.96 ± 8.411 | — | 61.23 ± 9.02 |
Collected over 12 Months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1 | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| Arm 2 | 0/5 (0%) | 1/5 (20%) | 5/5 (100%) |
| Arm 3 | 0/8 (0%) | 4/8 (50%) | 8/8 (100%) |
| Arm 4 | 0/8 (0%) | 4/8 (50%) | 8/8 (100%) |
| Arm 5 | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| Event | Arm 1 | Arm 2 | Arm 3 | Arm 4 | Arm 5 |
|---|---|---|---|---|---|
| Delayed Graft FunctionInjury, poisoning and procedural complications | 2/6 | 0/5 | 0/8 | 0/8 | 0/5 |
| Duodenal ulcer haemorrhageGastrointestinal disorders | 0/6 | 1/5 | 0/8 | 0/8 | 0/5 |
| New onset Diabetes after transplantationMetabolism and nutrition disorders | 1/6 | 0/5 | 0/8 | 0/8 | 0/5 |
| Focal Segmental GlomerulosclerosisRenal and urinary disorders | 1/6 | 0/5 | 0/8 | 0/8 | 0/5 |
| Renal ImpairmentRenal and urinary disorders | 1/6 | 0/5 | 0/8 | 0/8 | 0/5 |
| LymphoceleVascular disorders | 1/6 | 0/5 | 0/8 | 0/8 | 0/5 |
| PancreatitisGastrointestinal disorders | 0/6 | 0/5 | 0/8 | 1/8 | 0/5 |
| Transplant RejectionImmune system disorders | 0/6 | 0/5 | 0/8 | 1/8 | 0/5 |
| AppendicitisInfections and infestations | 0/6 | 0/5 | 1/8 | 0/8 | 0/5 |
| Pulmonary NocardiosisInfections and infestations | 0/6 | 0/5 | 1/8 | 0/8 | 0/5 |
| Event | Arm 1 | Arm 2 | Arm 3 | Arm 4 | Arm 5 |
|---|---|---|---|---|---|
| Polyomavirus viraemiaInfections and infestations | 4/6 | 0/5 | 1/8 | 1/8 | 1/5 |
| HypertensionVascular disorders | 4/6 | 3/5 | 4/8 | 2/8 | 1/5 |
| Cytomegalovirus viraemiaInfections and infestations | 3/6 | 0/5 | 5/8 | 1/8 | 0/5 |
| LeukopeniaBlood and lymphatic system disorders | 3/6 | 1/5 | 4/8 | 2/8 | 2/5 |
| DiarrhoeaGastrointestinal disorders | 2/6 | 0/5 | 4/8 | 1/8 | 2/5 |
| NauseaGastrointestinal disorders | 3/6 | 0/5 | 2/8 | 0/8 | 0/5 |
| Oedema peripheralGeneral disorders | 3/6 | 0/5 | 2/8 | 0/8 | 0/5 |
| BK virus infectionInfections and infestations | 3/6 | 0/5 | 1/8 | 0/8 | 1/5 |
| NasopharyngitisInfections and infestations | 3/6 | 0/5 | 3/8 | 0/8 | 1/5 |
| HyperkalaemiaInvestigations | 2/6 | 0/5 | 4/8 | 2/8 | 2/5 |
One participant was randomized, but never received Study Drug and was never received any study procedure during their screening period. Baseline characteristics were collected.
| Age, Continuous(Years) | Arm 1 | Arm 2 | Arm 3 | Arm 4 | Arm 5 | Total |
|---|---|---|---|---|---|---|
| Mean | 48.8 ± 7.76 | 52.2 ± 15.37 | 58.1 ± 7.13 | 49.5 ± 12.71 | 48.6 ± 9.29 | 52 ± 10.65 |
| Sex: Female, Male(Participants) | Arm 1 | Arm 2 | Arm 3 | Arm 4 | Arm 5 | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 0 | 2 | 4 | 2 | 10 |
| Male | 4 | 5 | 7 | 4 | 3 | 23 |
| Race (NIH/OMB)(Participants) | Arm 1 | Arm 2 | Arm 3 | Arm 4 | Arm 5 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 | 0 | 0 | 2 |
| White | 5 | 4 | 8 | 7 | 5 | 29 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1 | Arm 2 | Arm 3 | Arm 4 | Arm 5 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 2 | 2 | 2 | 6 |
| Not Hispanic or Latino | 6 | 5 | 6 | 6 | 3 | 26 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | Arm 1 | Arm 2 | Arm 3 | Arm 4 | Arm 5 | Total |
|---|---|---|---|---|---|---|
| Austria | 4 | 1 | 4 | 1 | 1 | 11 |
| Sweden | 2 | 4 | 3 | 5 | 2 | 16 |
| Spain | 0 | 0 | 2 | 2 | 2 | 6 |
| Height(cm) | Arm 1 | Arm 2 | Arm 3 | Arm 4 | Arm 5 | Total |
|---|---|---|---|---|---|---|
| Mean | 176.33 ± 11.112 | 177.4 ± 7.369 | 172.63 ± 172 | 173.25 ± 8.828 | 172 ± 11.79 | 174.44 ± 9.059 |
| Weight(Kg) | Arm 1 | Arm 2 | Arm 3 | Arm 4 | Arm 5 | Total |
|---|---|---|---|---|---|---|
| Mean | 80.183 ± 19.372 | 81.82 ± 20.141 | 76.725 ± 15.909 | 80.488 ± 10.999 | 82.160 ± 10.914 | 79.959 ± 14.7251 |
| BMI(kg/m^2) | Arm 1 | Arm 2 | Arm 3 | Arm 4 | Arm 5 | Total |
|---|---|---|---|---|---|---|
| Mean | 25.72 ± 5.627 | 26 ± 6.050 | 25.64 ± 4.262 | 26.81 ± 2.918 | 27.26 ± 3.713 | 26.26 ± 4.247 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2021 to primary completion in Dec 2024, 42 months.
Results were first posted in Mar 2026, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Siplizumab
ITB-Med LLC